Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gunagratinib in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
NCT05678270Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Nov 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gunagratinib in intrahepatic cholangiocarcinoma (ICC), sponsored by InnoCare Pharma. Primary endpoint: Objective Response Rate up to 3 years. Started Nov 2022; status: recruiting.
02
Drugs
gunagratinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05678270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678270.